Video

Dr. Shore on the Importance of Genetic Testing in Prostate Cancer

Neal Shore, MD, discusses the importance of incorporating genetic testing into treatment strategies for patients with prostate cancer.

Neal Shore, MD, FACS, U.S. chief medical officer of Surgery and Oncology, GenesisCare, director, CPI, Carolina Urologic Research Center, discusses the importance of incorporating genetic testing into treatment strategies for patients with prostate cancer. 

Genetic testing has historically occupied a more theoretical niche in prostate cancer treatment, Shore states. However, identifying specific genetic mutations can help guide treatment decisions in prostate cancer and identify patients and their family members who may be at risk of developing other types of cancer, Shore continues.

In prostate cancer, approximately 10% to 12% of patients with high-risk localized disease, inclusive of metastatic disease, and/or a significant family history will harbor a homologous recombinant repair (HRR) alteration, Shore notes.

Patients who carry a heritable HRR gene mutation, such as BRCA, could therefore be successfully identified through screening, allowing family members to undergo cascade testing, Shore continues. This could enable earlier identification of prostate cancer and other known BRCA-mutated cancers in family members carrying the mutation, Shore concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity